Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial

The European Organisation for Research and Treatment of Cancer (EORTC) 1325-MG/KEYNOTE-054 trial in patients with resected, high-risk stage III melanoma demonstrated improved recurrence-free survival with adjuvant pembrolizumab compared with placebo (hazard ratio 0·57 [98·4% CI 0·43–0·74]; p

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The lancet oncology 2021-05, Vol.22 (5), p.655-664
Hauptverfasser:	Bottomley, Andrew, Blank, Christian U, Mandalà, Mario, Long, Georgina V, Atkinson, Victoria G, Khattak, Adnan, Carlino, Matteo S, Sandhu, Shahneen, Puig, Susana, Larkin, James, Lorigan, Paul C, Rutkowski, Piotr, Schadendorf, Dirk, Koornstra, Rutger, Hernandez-Aya, Leonel, Di Giacomo, Anna Maria, van den Eertwegh, Alfonsus J M, Grob, Jean-Jacques, Gutzmer, Ralf, Jamal, Rahima, Krepler, Clemens, Marreaud, Sandrine, Kicinski, Michal, Robert, Caroline, Lesimple, Thierry, Maio, Michele, Linette, Gerald, Mortier, Laurent, Svane, Inge Marie, Schachter, Jacob, Brown, Michael, Hersey, Peter, Barrow, Catherine, Kudchadkar, Ragini, Song, Xinni, Quaglino, Pietro, Queirolo, Paola, Stroyakovskiy, Daniil, Romero, Pablo Luis Ortiz, Bastholt, Lars, Garbe, Claus, Grange, Florent, Mohr, Peter, Bechter, Oliver, Loquai, Carmen, Meiss, Frank, Bar-Sela, Gil, Fitzharris, Bernard, Saiag, Philippe, Arnault, Jean-Philippe, Baurain, Jean-Francois, Combemale, Patrick, Dummer, Reinhard, Hauschild, Axel, Yamazaki, Naoya, Milhem, Mohammed, Kretschmer, Lutz, Dunwoodie, Elaine, Walker, John, Hendler, Daniel, Dzienis, Marcin, Hospers, Geke A.P., Hassel, Jessica, Passos, Maria-Jose, Levin, Max, Hoeller, Christoph, Machet, Laurent, Hallmeyer, Sigrun, Waterston, Ashita, Descamps, Vincent, Kiecker, Felix, Aarts, Maureen, Schmidt, Henrik, Raimundo, Ana, Lacour, Jean-Philippe, Berking, Carola, Ferrucci, Pier Francesco, Jameson, Michael, Kim, Kevin, Yokota, Kenji, Aubin, François, Kapiteijn, Helena, Boehncke, Wolf-Henning, Utikal, Jochen, Casasola, Richard, Marshall, Ernest, Richtig, Erika, Matkovic, Suzana, Crook, Timothy, Kiyohara, Yoshio, Avril, Marie-Francoise, Hein, Rüdiger, Nathan, Paul, Aoi, Jun, Skytta, Tanja, Jouary, Thomas, Takenouchi, Tatsuya, Straume, Oddbjorn, Martins, César, Mukhametshina, Guzel
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antibodies, Monoclonal, Humanized Antibodies, Monoclonal, Humanized - therapeutic use Cancer Cancer therapies Clinical medicine Clinical trials Double-Blind Method Double-blind studies Drug therapy Dyspnea Female Humans Immunotherapy Life Sciences Lymphatic system Male Medical research Melanoma Melanoma - drug therapy Melanoma - mortality Melanoma - pathology Melanoma - psychology Metastasis Middle Aged Monoclonal antibodies Neoplasm Staging Patients Pembrolizumab Placebos Population studies Public health Quality of Life Skin Neoplasms Skin Neoplasms - drug therapy Skin Neoplasms - mortality Skin Neoplasms - pathology Skin Neoplasms - psychology Survival Targeted cancer therapy Toxicity
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The European Organisation for Research and Treatment of Cancer (EORTC) 1325-MG/KEYNOTE-054 trial in patients with resected, high-risk stage III melanoma demonstrated improved recurrence-free survival with adjuvant pembrolizumab compared with placebo (hazard ratio 0·57 [98·4% CI 0·43–0·74]; p
ISSN:	1470-2045 1474-5488
DOI:	10.1016/S1470-2045(21)00081-4